22 August 2022
ECO Animal Health Group plc
(''ECO", the "Company" or the "ECO Group") (AIM: EAH)
REVISED NOTICE OF RESULTS
ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, today announces a revised date for the publication of its preliminary results for the year ended 31 March 2022.
The Company's auditor, BDO LLP, has requested additional time to complete its audit completion procedures. As a result, the Company now expects to announce its final results on 31 August 2022.
As previously announced in the trading update on 8 August 2022, the Group expects to report full-year results for the year ended 31 March 2022 with revenue of approximately £82.2 million (2021: £105.6 million) and an EBITDA of approximately £6.4 million which includes an exchange rate gain of £1.0 million.
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
For further information please contact:
| ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
| 020 8447 8899
|
|
IFC Advisory Graham Herring Zach Cohen
|
020 3934 6630
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas |
020 7496 3000 |
|
Investec (Joint Broker) Gary Clarence Brough Ransom Carlo Spingardi
Peel Hunt LLP (Joint Broker) Dr Christopher Golden James Steel |
020 7597 5970
020 7418 8900 |
| Equity Developments Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.
END
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
